IMABI-Mab - ADR

$1.65
$0.155
(8.61%)
Today
Closed $1.65
$0.065
(3.95%)
After Hours
Updated: 07:58 PM EDT
Reported EarningsAug 20
Mkt Cap$189.8M
Vol598,677.00
50

Neutral Sentiment

How do you feel about IMAB?

News
all
press releases
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMAB
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMAB INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMAB PR Newswire...
PR Newswire
News Placeholder
More News
News Placeholder
Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge
Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge PR Newswire VANCOUVER, BC, Oct. 15, 2025 Equity Insider News...
PR Newswire
News Placeholder
I-Mab Sponsored ADR (IMAB) Is Up 24.14% in One Week: What You Should Know
Does I-Mab Sponsored ADR (IMAB) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks
News Placeholder
What Makes IMab (IMAB) a New Buy Stock
IMab (IMAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
News Placeholder
Are You Looking for a Top Momentum Pick? Why I-Mab Sponsored ADR (IMAB) is a Great Choice
Does I-Mab Sponsored ADR (IMAB) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks
News Placeholder
I-Mab Sponsored ADR (IMAB)'s Technical Outlook is Bright After Key Golden Cross
Zacks
News Placeholder
I-Mab Sponsored ADR (IMAB) is a Great Momentum Stock: Should You Buy?
Zacks
<
...
1
>

Advertisement|Remove ads.